Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

Sodium Phenylbutyrate
  • Compare to
    Buphenyl®*
*Buphenyl® is a registered trademark of Horizon Pharma, Inc.

Sodium Phenylbutyrate Powder (250 grams)

  • Package size
    3 g/Tsp
  • Rating
    AB
  • Strength
    250 g
  • NDC Code
    42794-0086-14
Sodium Phenylbutyrate Powder (250 grams)

 

* Disclaimer: All images shown are for illustrative purposes only. Actual product may vary due to image enhancement. The images and information for a particular product may change over time. For the most up-to-date product information, please contact Sigmapharm Laboratories, LLC.